Pagina 2 - I migliori medici per il trattamento di Tumore della prostata - TOP-145 medici

Activities • Prevention, research and early diagnosis of cancer • Palliative care in cancer • Cytotoxic chemotherapy • Hormontherapy • Targeted treatment • Immunotherapy Education • 2004 -2010 - Istanbul University, Istanbul faculty of medicine • 2011-2015 - Istanbul University, Istanbul faculty of medicine, internal medicine specialist • 2013-2014 - Cleveland Clinic Endocrinology Department, research associate • 2016-2019 Bezmiâlem Foundation University Medical Oncology Subdivision • Dissertation: Prognostic value of absolute monocyte count in patients with mantle cell lymphoma. • Subdivision Dissertation: An effect of adjuvant chemotherapy on lipid profile and anthropometric parameters in patients with breast and colon cancer. Publications • Circulating Thyroid-Stimulating Hormone Receptor Messenger RNA as a Marker of Tumor Aggressiveness in Patients with Papillary Thyroid Microcarcinoma. Aliyev A, Gupta M, et al. Endocr  18. • The utility of peripheral thyrotropin receptor mRNA in the management of differentiated thyroid cancer. • Aliyev A, Soundararajan S, Bucak E et al. Surgery.  • Diagnostic accuracy of circulating thyrotropin receptor messenger RNA combined with neck ultrasonography in patients with Bethesda III-V thyroid cytology. Aliyev A, Patel J, Brainard J, et al. Surgery.2016 Jan;159(1):113-7. doi: 10.1016/j.surg.2015.06.063. Epub 2015 Oct 9. • Role of Urotensin-2 in 5-Fluorouracil-Related Arterial Vasoconstriction in Cancer Patients. Seker M, Aliyev A, et al. Oncol Res Treat. Epub 2018 Aug 20. • Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naive breast cancer: real-life practice outcomes. Esin E, Oksuzoglu B, Bilici A, Aliyev A. Cancer Chemother Pharmacol.2019 Jan; Epub 2018 Oct 30. • Usefulness of serum M30 and M65 levels to predict response to neoadjuvant chemotherapy in patients with breast cancer. Turk HM, Aliyev A, Celik RS. Curr Probl Cancer.2019 Jul 29. pii: currproblcancer.2019.06.009. • Prognostic impact of primary tumor location on survival in metastatic colorectal cancer patients: A single center experience. Tarik Demir, Murat Araz, Altay Aliyev. Medicine Science International Medicine Journal. • Oral presentations 

Personal information

Title: Professor Doctor

Branch: Radiation Oncology

Work History:

1 GATA Military Medical Faculty

2 Gayrettepe Florence Nightingale Hospital

3 T.R. Demiroğlu Bilim University \ Associate Professor

4 T.R Demiroğlu Bilim University \ Professor

Medical Specialties and Subspecialties:

1 Head and Neck Cancers

2 Radiation Oncology

Priority treatments:

1 Prostate cancer

2 Conformal treatments

Special advanced health technologies:

1 Truebeam Stx Technology

2 Halcyons

Education

1991 - Istanbul University Istanbul Faculty of Medicine

1996 - Istanbul University Cerrahpaşa Faculty of Medicine Radiation

Oncology Specialization Training

Education/Academic Experience

Apr 1995 – Oct 2001                Medical School of Aristotle University of Thessaloniki, Greece

Mar 2007                                   IELTS Certificate (Overall Band Score 7.5)

Feb 2011                                    CCST in Urology, Aristotle University of Thessaloniki, Greece

June 2012                                  Fellow of the European Board of Urology (FEBU)

Sept 2014                                  Fellow in Andrology/Reconstructive Surgery (Mr Giulio Garaffa,         UCLH / Mid-Essex)

Apr 2016                                   Fellow of the Royal College of Surgeons of England (FRCS Eng)

Oct 2018                                   Honorary Senior Lecturer St Andrews University

Sep 2019                                   Urology ChM Tutor in Andrology and Minimally Invasive Surgery (MIMS) University of Edinburgh

Aug 2020                                  European Union Expert Panel Member of in vitro Medical Devices (EU EXPAMED)

Current and Previous appointments

Current appointment

May 2022- Present         Consultant Urologist German Oncology Centre, Limassol, Cyprus

Previous appointments

Nov16- May 2021       Consultant Urological Surgeon Victoria/ Queen Margaret Hospital Fife, Scotland.

Nov 2012 - Oct 2016      Consultant Urologist Broomfield Hospital, Mid-Essex Hospitals Trust 

Jan 2011 - Oct 2012      Urology Clinical Research Fellow, Spelialist Registrar Level), Bristol Royal Infirmary, United Bristol Hospitals Trust

Dec 2009 -Dec 2010      Urology Resident G. Gennimatas Hospital, Aristotle University of Thessaloniki

Duties

• Performing routine and major Penile / Urethral Reconstruction as well as Core Urology procedures twice weekly at Victoria and Queen Margaret Hospitals (Green light prostatectomy, Urolift Service lead, Prostate template biopsies, General urology)

Consultant Urologist providing and supervising the services of andrology and urethral reconstruction surgery. Also covering a general urology one stop outpatient clinics three times per week (Victoria and Queen Margaret Hospitals).

Participation in once weekly local cancer and once monthly specialist male uro-genital reconstruction MDT meetings (Honorary contract at the Western General Hospital, Edinburgh) as well as grand ward rounds.

Undergraduate student trainer and member of examiners panel at St Andrews University, Scotland.

Participation in 1:9 on call Urology Consultant rota.

Research

• Victoria Hospital, Kirkcaldy (NHS Fife) lead investigator. A prospective, multicentre study with subgroup randomisation into MRI-U/S image fusion guided prostate biopsies and routine transrectal U/S guided biopsies.  (MULTIPROS Study)
•  
• Broomfield Hospital (MEHT) sub-investigator. A pragmatic multicentre randomised superiority trial of open urethroplasty versus endoscopic urethrotomy. (OPEN Study)
•  
• Broomfield Hospital (MEHT) sub-investigator. A Multicentre randomised controlled trial of extracorporeal shockwave lithotripsy, as first treatment option, compared with direct progression to ureteroscopic treatment, for ureteric stones. (TISU
• Study)
•  
• Bristol Royal Infirmary sub-investigator. A Multicentre Randomised Controlled Trial of the Use of Drug Therapy in the Management of Symptomatic Ureteric Stones in Hospitalised Patients. (SUSPEND Study)
•  
• Bristol Royal Infirmary sub-investigator. A Multicentre Prospective Single Arm Intervention Trial Evaluating Focal Therapy using High Intensity Focused Ultrasound (Sonablate 500) for Localised Prostate Cancer. (HIFU INDEX Study)
•  
• Bristol Royal Infirmary sub-investigator, A Randomised Controlled Trial to Determine the Effect of Decapeptyl on Reduction of Prostate Volume Pre-Radiotherapy Compared with Standard Therapy (Zoladex). (EDVART Study)

Teaching Experience

Fife Simulation BPH Course Fascilitator (Scottish Urology Training Programme, Queen Margaret Hospital, Dumfermline Fife)

Urology Simulation boot camp Faculty member (St James's University Hospital, Leeds)

General Practitioner Urology Training Programme Fascilitator (ScotGem)

Objective Structured Clinical Examination (OSCE) assessor (St Andrews University Medical School)

Teaching (case-based discussions) and trainee supervision in theatres (East Anglia / East of   Scotland Deaneries trainees)

FY1 Doctors Urology teaching Bristol Royal Infirmary (University Bristol Hospitals Trust)

Undergraduate teaching of medical students in General Hospital of the city of Drama, Greece

Anatomy, Physiology and First Aid to Undergraduate nursing students

Education and Specialization

• Faculty of Medicine, Hacettepe University
• 1999 - Akdeniz University, Faculty of Internal Medicine, Internal Medicine Specialization Training
• Internal Medicine Specialization Training in the USA, Akdeniz University (2013 - 2014)
• Internal Medicine Specialization Training in the USA (2013 - 2014) - Medical Oncology Department
• Akdeniz University, Faculty of Medicine, Department of Medical Oncology (Received Associate Professorship title)

Work Experience

• 2009 - Kayseri Training and Research Hospital, Hospital
• Acıbadem Kayseri
• 2017 - 2018 - Lara Private Anadolu Hospital
• 2018 - Medical Park Antalya Hospital Complex

Expertise

• Diagnosis of organ tumors
• Chemotherapy in cancer treatment
• Targeted cancer therapies
• Immunotherapy in cancer treatment
• Next-generation genetic research in cancer treatment
• Complementary medicine in cancer treatment
• Medical oncology

Dr. Shira Felder is a senior radiation oncologist. She focuses on gynecologic and urologic cancers. She has advanced expertise in VMAT, IMRT, SBRT, and gynecologic brachytherapy. She delivers precise treatment with fewer side effects.

She heads the Gynecologic Oncology Service at Sheba Medical Center. She is a senior physician in the Radiation Oncology Division. She earned her MD at Hadassah. She completed residency at Sheba and a fellowship in the Radiation Medicine Program at the University of Toronto and Princess Margaret Cancer Centre. She is board-certified in Radiation Oncology. She is a member of ESTRO, the Israeli oncology societies, the CPSO, and the CMA.

Her research covers brachytherapy patient safety. It also includes stereotactic ablative radiotherapy for stage I lung cancer. She has studied treatment delays in cervical cancer. She has examined vitamin D deficiency in oncology patients.

Dr. Antonio Alcaraz is a Spanish uro-oncologist and transplantologist with over 30 years of experience and 500 successful operations, specializing in the treatment of prostate cancer, kidney, bladder, and other urogenital system pathologies using minimally invasive and robotic systems, as well as congenital pathologies in children. He is a member of several prestigious urological societies.

Dr. Yuri Goldes is a general surgeon with more than 20 years of clinical experience. He specializes in upper gastrointestinal and oncologic surgery. He is Deputy Director of the Department of General Surgery and Transplantation at Sheba Medical Center in Tel Aviv. He also leads the Upper GI Surgery Unit. He was named to Forbes Israel’s Best Doctors in 2025. He is ranked among Israel’s Best Gastrointestinal Surgeons by Forbes. In 2019, he received the Israeli Ministry of Health “Best Doctor of the Year” award.

He is an expert in advanced minimally invasive and robotic surgery. He treats diaphragmatic hernia, achalasia, GERD, and gallbladder disease. He also performs oncologic surgery for pancreatic, gastric, and esophageal cancers. He uses laparoscopic and robotic techniques.

He pioneered some of Israel’s first robotic oncologic resections of the stomach and pancreas. He is among a small group worldwide who perform minimally invasive Whipple procedures (pancreaticoduodenectomy) using advanced laparoscopy. He applies methods that improve outcomes and speed recovery. He provides personalized care.

Dr. Osama Abdel Mohimen Mohamed is Head of the Hematology Unit at Shefaa Al Orman Oncology Hospitals. He is also a consultant in medical oncology and hematology at Shefa El Orman Hospital (NGO), Luxor (2019–present).

He diagnoses and treats acute and chronic leukemia, lymphoma, myeloma, myelodysplastic syndromes, and myeloproliferative neoplasms. He also manages complications of solid tumors.

Background: He served at the National Cancer Institute, Cairo University, as a medical oncology resident, then demonstrator and assistant lecturer (2008–2022). Earlier, he was a house officer (2006–2007). He also held specialist roles at Al Salam International, Al Molalmen, and BAHEYA Oncology Center (NGO).

Memberships: ESMO (2008–present). American Society of Bone Marrow Transplantation (2009). ASH (2010).

Experience

2022 PRIVATE MEDIPOL BAHÇELİEVLER HOSPITAL

2021 - 2021 Prof. Dr. Cemil Taşçıoğlu City Hospital, Medical Oncology Clinic Education Officer

2021 - 2021 Prof. Dr. Cemil Taşçıoğlu City Hospital

2020 - 2021 Yüzüncü Yıl University Faculty of Medicine

2020 - 2021 Head of the Department of Medical Oncology, Yüzüncü Yıl University Faculty of Medicine, Assoc. Dr.  

2018 - 2021 Lecturer - Yüzüncü Yıl University Faculty of Medicine, Head of Medical Oncology Department  

2018 - 2021 Yüzüncü Yıl University Faculty of Medicine

2015 - 2018 University of Health Sciences, Okmeydanı Training and Research Hospital

2015 - 2018 University of Health Sciences, Okmeydanı Training and Research Hospital, Medical Oncology Clinic, Sub-branch assistant

2012 - 2015 Kanuni Sultan Süleyman Training and Research Hospital, Internal Medicine specialist

2012 - 2015 Suleiman the Magnificent Training and Research Hospital,

2008 - 2012 Haseki Training and Research Hospital

2006 - 2008 Kızıltepe No. 3 Health Center General Practitioner.

Education

2018

İstanbul Okmeydanı Eğitim ve Araştırma Hastanesi, Tıbbı Onkoloji

2018

İstanbul Okmeydanı Eğitim ve Araştırma Hastanesi, Tıbbı Onkoloji, İstanbul Okmeydanı Eğitim ve Araştırma Hastanesi, Tıbbı Onkoloji

2012

İstanbul Haseki Eğitim ve Araştırma Hastanesi, İç Hastalıkları, İstanbul Haseki Eğitim ve Araştırma Hastanesi, İç Hastalıkları

2012

İstanbul Haseki Eğitim ve Araştırma Hastanesi, İç Hastalıkları

2007

Uludağ Üniversitesi Tıip Fakültesi, Tıip Fakültesi, Uludağ Üniversitesi Tıip Fakültesi, Tıip Fakültesi

Dr. Enrique Grande, MD, PhD, MSc, is a medical oncologist with more than 20 years of experience. He is an international expert in genitourinary and neuroendocrine tumors. He directs the Medical Oncology Department and the One Oncology Madrid Cancer Program at QuirónSalud, Spain’s largest private healthcare network. He leads an integrated, multidisciplinary model with access to targeted therapies and clinical trials.

He is a pioneer in precision oncology. He uses molecular profiling and biomarker-based care. He has authored more than 300 peer-reviewed papers. He serves as a principal investigator and sits on steering committees for many international trials. These studies help set standards of care in urothelial bladder and neuroendocrine tumors. He contributes to guidelines and programs at ESMO, ASCO, ENETS, and EAU.

Education

09 / 2004 – 07 / 2006                Movie Director School, ANT1 Movie School Athens, Greece, Degree “Television Director”, grade point average: B

09 / 2006 – 08 / 2008                Medical School, Semmelweis University Budapest, Hungary, Medical preliminary examination (Physikum), grade point average: A

10 / 2008 – 05 / 2013                Medical School, Albert-Ludwigs-Universität Freiburg, Germany, State examination in medicine, grade point average: A

02/ 2009 – 02/2012                   Institute of Pharamcology and Toxicology I, Albert-Ludwigs-Universität Freiburg, Germany, Doctoral thesis, grade: summa cum laude

05 / 2018                                      Basic and advanced course in German drug law and GCP, Clinical Trials Unit, Medical Center - University of Freiburg

01 / 2019                                      Board certification: Radiotherapy and Radiation Oncology

03 / 2020                                      Medical Center University of Freiburg, Department of Radiation Oncology, Germany, Habilitation (Postdoctoral lecture qualification)

09 / 21 – 08 / 23                         MHBA, Friedrich Alexander University, Nuernberg, Germany

07 / 2022                                      Completion of ISO 9001:2015 training, Nicosia, Cyprus

Professional Career

09 / 2013 – 01 / 2019               Medical Center University of Freiburg, Department of Radiation Oncology, Germany, Residency                                                

07 / 2017 – 07 / 2020               Bertha-Ottenstein programme, Medical Center, University of Freiburg, Germany, Clinician Scientist

Since 06 / 2019                          Medical Center University of Freiburg, Department of Radiation Oncology, Germany, Consultant

01 / 2021 – 12 / 2022                Bertha-Ottenstein programme, Medical Center, University of Freiburg, Germany, Advanced Clinician Scientist

01 / 2021 – 12 / 2021                 Head of the section “Interventional Radiation Oncology”, Medical Center University of Freiburg, Department of Radiation Oncology, Germany

Since 01 / 2022                         Medical Center University of Freiburg, Department of Radiation Oncology, Germany, Prostate cancer research group leader

Since 01 / 2022                          German Medical Institute, Limassol, Cyprus, Vice Medical Director

Professional Memberships and Distinctions

2010           Sanofi-Aventis poster prize, Annual meeting of the German Society of Pharmacology and Toxicology 2010, Mainz, Germany      

2017           Poster prize, Annual meeting of the German Society of Radiation Oncology (DEGRO) 2017, Berlin, Germany

2019           Poster prize, Uro-Oncological Symposium 2019, Magdeburg, Germany

2020           Invited member of the German expert panel for prostate cancer of the German Society of Radiation Oncology (DEGRO)

2020           Herman-Holthusen Award, German Society of Radiation Oncology (DEGRO)

2021           Invited member of the ESTRO-ACROP guideline committee for prostate cancer

2021           Best Abstract, EMUC congress 2021, Athens, Greece

2023           Annual ARO study price for the HypoFocal-SBRT study from the German Cancer Foundation

2023           Invited member of the ESTRO focus group “Urology”

• Education: 
•  
• 2001-2007: University of Ioannina Medical School, Greece.
• 2007: Degree in Medicine.
• 2013: Doctoral degree from the Medical School of the Johann Wolfgang Goethe University, Frankfurt (Dr. Med)
• 09.2016 – Today: Master’s in Healthcare Business Studies.

Professional experience:

04.2009 – 04.2013: Resident in the Department for Radiation Oncology, Klinikum Offenbach

05.2013 – 12. 2015: Senior physician in the Department for Radiation Oncology, Klinikum Offenbach

• 01.2016 – 06.2017: Senior physician in the Department of interventional Radiation Oncology, Medical Center Athens
•  
• 07.2017 – Today: Head of the Department of Radiation Oncology at the German Oncology Center, Limassol, Cyprus.

Il Dr. Sinan Karaaslan ha eseguito oltre 900 procedure, specializzandosi nel trattamento del cancro alla prostata presso il Centro Medico Anadolu.

• 28 anni di esperienza in oncologia medica
• Esperto in chirurgia, radioterapia, terapia ormonale e chemioterapia per il cancro alla prostata
• Membro della Società Turca di Oncologia Medica
• Formazione presso la Scuola di Medicina Cerrahpaşa dell'Università di Istanbul

Il Prof. Dott. Serkan Keskin è un oncologo medico di primo livello in Turchia, specializzato in trattamenti avanzati per il cancro alla prostata presso il Memorial Şişli Hospital.

• Oltre 28 anni di esperienza in oncologia
• Esperto in immunoterapia e terapie mirate
• Pioniere nella mappatura genetica per trattamenti personalizzati
• Membro attivo di ASCO ed ESMO
• Ha pubblicato oltre 50 articoli internazionali con più di 1.100 citazioni

La professoressa Yesim Yildirim, membro dell'ESMO, è specializzata in immunoterapia del cancro e terapie mirate presso l'Anadolu Medical Center.

• Autrice di oltre 80 pubblicazioni, comprese capitoli in manuali di oncologia
• Professoressa presso l'Università di Haliç, una delle principali istituzioni della Turchia
• Formata in centri prestigiosi come il Mount Vernon Cancer Center di Londra
• Certificata ESMO con competenze in approcci di medicina di precisione

Il Professor Şeref Kömürcü è un oncologo mammario certificato ECFMG e ESMO con oltre 20 anni di esperienza. Si specializza in tumori solidi, cancro al seno, cancro colorettale e trattamento del cancro ai polmoni e, nel corso della sua carriera, ha ricoperto incarichi accademici e di ricerca. È membro di diverse organizzazioni professionali.

Dr. Rahib Hasanov is a medical oncologist. He graduated from Istanbul University Cerrahpaşa Faculty of Medicine (1999–2005). He completed an internal medicine residency (2009–2013) and a medical oncology fellowship at Marmara University (2015–2018). He also completed an observership at Houston Methodist Hospital (2006–2007).

He focuses on personalized oncology. His treatments include immunotherapy, targeted therapy, and novel agents. His clinical interests include gastrointestinal, breast, lung, and genitourinary cancers.

He attends national and international conferences. He welcomes patients from Turkey, Azerbaijan, Montenegro, Georgia, Uzbekistan, the Middle East, Europe, and the United States.

Prof. Dr. Sezer Sağlam is a medical oncologist at Gayrettepe Florence Nightingale Hospital. He specializes in gastrointestinal and breast cancers. He has contributed to cancer care through research, especially with his study on the best timing for surgery after neoadjuvant therapy in rectal cancer. This work has influenced global treatment protocols.

Dr. Sağlam has led clinical trials in targeted therapies and precision medicine. His research on liver-transplanted patients with hepatocellular carcinoma was nominated for the 2024 International Best Researcher Award. He is a member of ASCO, ESMO, and ENET. Dr. Sağlam provides personalized and evidence-based oncology care.